Bylvay denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for bylvay are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Bylvay as Non-Formulary

A non-formulary denial from Blue Cross Blue Shield means Bylvay (odevixibat) is not included on your specific plan's preferred drug list, or it appears on a tier that requires additional authorization before coverage is granted. Non-formulary denials are not final — every commercially insured plan and most government-program plans must offer a formulary exception process, and for rare-disease drugs like Bylvay there is often no formulary alternative that treats the same condition.

## Why It Is Appealable

For a non-formulary denial to be upheld, the plan must be able to point to a formulary alternative that is clinically appropriate for your specific diagnosis and circumstances. If no such alternative exists, or if alternatives were tried and failed, the plan is required to grant a formulary exception. Your rights include:

• ACA §2719 / ERISA §503: Full internal appeal (formulary exception request) followed by independent external review.
• External review window: Approximately four months from the date of final internal denial — confirm on your Explanation of Benefits.
• Expedited review: Available when delay would seriously harm health; decision typically required within 72 hours.

## Appeal Process and Timeline

1. Request the non-formulary denial in writing and ask BCBS to identify which formulary alternative(s) it believes are clinically equivalent. 2. File a formulary exception request — this is a specific pathway distinct from a standard appeal and is often faster. 3. Simultaneously file or follow up with a formal internal appeal if the exception request is denied. 4. Escalate to external review if the internal process is exhausted.

## Documentation to Gather

• Diagnosis and indication match: Chart notes confirming your diagnosis falls within Bylvay's FDA-approved indication, demonstrating why this drug specifically is required.
• Formulary alternative failure history: For each drug BCBS identifies as a formulary alternative, provide documentation that it was tried and failed, was not tolerated, or is clinically inappropriate for your specific subtype.
• Prescriber medical-necessity and formulary exception letter: A clear statement that no formulary alternative is clinically equivalent for your diagnosis, referencing the FDA-approved indication and the applicable specialty-society guideline organization.
• Clinical severity evidence: Recent lab trends and chart notes showing the impact of undertreated disease, supporting the urgency of covering the non-formulary agent.

## Criteria-Mapping Structure

Review the FDA-approved prescribing information for Bylvay and BCBS's coverage policy side by side. Document each criterion and the chart fact that meets it. For the formulary exception specifically, your prescriber's letter should explicitly state why each proposed formulary substitute is inadequate — by mechanism, by labeled indication, or by documented trial outcome.